Trump Twitter Hangover Keeps Biotech Stocks Down: Update-1

Update-1…1/24/17…Bit of a Rally Leaves Out Healthcare Stocks Markets rallied a bit today but biotech and drug stocks remain stalled by the Trump triggered bashing two weeks ago. Moreover traders are back to nibbling at the infrastructure theme with materials up 2.3% and energy up 1.09%. Large cap drug stock earnings are coming later this […]

Continue Reading 0

2017 J.P.Morgan Healthcare Conference: Large Cap Biotechs Compared to 2016

Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat. Selected stocks that continued their upward trend from earlier this week are: Array Biopharma (ARRY) up 7.3%  -Five […]

Continue Reading 0

J.P. Morgan Healthcare Conference Notes #2: Sun is Out but Trump Storm Hits Biotech Stocks

Biotech Rally Snuffed Out Again By Tough Trump Talk  on Drug Pricing  Any market optimism from the Conference about new product pipelines, M&A and “read-outs” on clinical data was chilled by Trump’s idea to let Medicare negotiate for better drug prices a perennial idea by DEMs in previous years. During the Trump news conference at […]

Continue Reading 0

2017 J.P.Morgan Healthcare Conference Notes #1: Investors Buy Selective Biotech Stocks-ILMN, INCY, REGN,RDUS

Wet Stormy Weather in San Francisco-A New Indicator for a Good Year Ahead? About 8000+ investors, entrepreneurs and life science Company executives piled into the Westin St. Francis for the Annual J.P.Morgan Healthcare Conference and maybe 10k+ others at several other surrounding hotel venues to hear the latest updates on new products, deals and financial […]

Continue Reading 0

J.P. Morgan Healthcare Conference This Week: ARIA

We will publish updates this week from the Conference. As of 3:45p EST the biotech sector is rallying. The IBB is up 1.6% and the XBI is up 3.5%. Biotech stocks were helped by the buyout of Ariad Pharmaceuticals (ARIA) by Takeda Pharmaceuticals in a deal worth $5.2B. ARIA stock was up 72.8%.

Continue Reading 0

Wet and Wild AR Storms Hit the West Coast: LaNina Madness

AR Storms Deliver Record Precipitation-The “Pineapple Express” By now you know it seems like the coldest wettest and coldest winter on the West Coast and the next week will bring even bigger “atmospheric river” storms. Here is an update as well as weather resources: First AR storm dumping 3.5 to 7ft at Mammoth Mountain, 145 […]

Continue Reading 1

Biotech Blahs: Out of Favor But Great For Stock Pickers…Update-2

Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the JPMorgan Healthcare Conference next Monday. Despite extremely negative sentiment on the sector, demand for […]

Continue Reading 0

Life Science Sector Review: Diagnostics and Tools Update

Life Science Sector: What’s Going On With Dx and Tools Stocks? We dropped coverage of Life Science diagnostics and tools stocks in January 2016 just after the severe market correction began. Of course the downdraft opened up great values in several stocks.We have reviewed selected stocks in the sector with the idea that more opportunities […]

Continue Reading 0

Biotechs Fade Again In Late Day Sell-Off

Biotechs Fade After Promising Start-Smaller Cap Winners Biotech stocks got a jump-start this morning peaked quickly then abruptly sold off at about 2p. The IBB ended down 1.33% to 268.79 off recent five-day highs of $274 and considerably off post-election highs of $293. The XBI tells  a similar story ending down 1.5% for the day […]

Continue Reading 0

Biotechs Mixed Hurt by Alexion (ALXN) and Ophthotech (OPHT)…Update-1

Update-1 2:30P EST… Improved Tone in Selective Biotech Stocks Maybe it’s bottom fishing or the end of tax selling but today we can see buyers coming in for large cap biotechs. However the backdrop is still cautious because of drug pricing rhetoric and a sector shift to industrials, energy and financials. But today could be […]

Continue Reading 0